bismuth has been researched along with Minimal Disease, Residual in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Axtman, A; Bäck, T; Fisher, DR; Frayo, S; Gopal, AK; Green, DJ; Hamlin, DK; Kenoyer, AL; Lin, Y; Orgun, N; Pagel, JM; Park, SI; Press, OW; Shenoi, J; Wilbur, DS | 1 |
1 other study(ies) available for bismuth and Minimal Disease, Residual
Article | Year |
---|---|
Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease.
Topics: Animals; Antibodies, Neoplasm; Antigens, CD20; Biotin; Bismuth; Blood Cell Count; Cell Line, Tumor; Humans; Immunoglobulin Variable Region; Kidney; Liver Function Tests; Lymphoma, Non-Hodgkin; Mice; Neoplasm, Residual; Organometallic Compounds; Radioimmunotherapy; Radiometry; Recombinant Fusion Proteins; Survival Analysis; Tissue Distribution; Xenograft Model Antitumor Assays | 2010 |